ALX Oncology (ALXO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALXO ALX Oncology

Watchlist

1.480
-0.030-1.99%

Close Nov 29 13:00 ET

1.490
+0.010+0.67%

Post 15:56 ET

78.06MMarket Cap-498P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 26 08:00 ET
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Zacks Nov 21 08:40 ET
Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dow JonesNov 14 08:00 ET
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings
BenzingaNov 12 08:43 ET
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
Moomoo NewsNov 11 07:34 ET · Ratings
ALX Oncology Highlights Promising Trial Results
TipRanksNov 8 23:25 ET

Comments

Teddy123

Nov 3 22:40

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

$ALX Oncology (ALXO.US)$
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced tha...

Jaguar8

Nov 1 16:31

NEWS

$ALX Oncology (ALXO.US)$
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...